Product-Specific J-Code for Omeros’ OMIDRIA® is Now in Effect

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the product-specific J-code for OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros’ commercial drug marketed for use during cataract surgery to prevent miosis and reduce postoperative pain. The new permanent J-code for OMIDRIA, J1097, replaces the previous temporary C-code C9447. J-codes are reimbursement codes used by commercial insurance plans, Medicare, Medi

Full Story →